Overview

A Phase 4 Study With Tamsulosin OCAS to Assess Nighttime Voiding.

Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
Randomized, double-blind, placebo-controlled study with two treatment arms (Tamsulosin OCAS 0.4 mg & placebo). The study comprises a 2-week placebo run-in followed by a 12-week treatment period.
Phase:
Phase 4
Details
Lead Sponsor:
Astellas Pharma Inc
Collaborators:
Astellas Pharma Europe Ltd.
Boehringer Ingelheim
Treatments:
Tamsulosin